Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Director | July 01, 2020 | July 02, 2020 |
| STAAR SURGICAL COSTAA · Entity 4851 | Director · President & CEO | March 05, 2025 | March 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date July 01, 2020 · Filed July 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2030-07-01 | Direct | 40,000 |
Reported balance
After 2020-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-01 · Grant · Acquired 40,000 · Balance 40,000 F1: Will become exercisable on July 1, 2021, based upon continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Will become exercisable on July 1, 2021, based upon continued service on the board of directors.
STAAR SURGICAL CO
Report date March 05, 2025 · Filed March 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,156 |
Ending reported balance
After 2025-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-03-05 · Exercise / conversion · Acquired 10,000 · Balance 25,156 Row 2 · 2025-03-05 · Exercise / conversion · Acquired 10,000 · Balance 35,156 |
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2026-06-23 | Direct | 0 |
Reported balance
After 2025-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-05 · Exercise / conversion · Disposed 10,000 · Balance 0 |
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2026-08-07 | Direct | 0 |
Reported balance
After 2025-03-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-05 · Exercise / conversion · Disposed 10,000 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Convey Health Solutions Holdings, Inc.
Report date October 07, 2022 · Filed October 12, 2022
Section 16 reporting ended · disclosed 2022-10-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 4,734 |
Reported balance
After 2022-10-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-10-07 · Disposition to issuer · Disposed 163,373 · Balance 4,734 F1: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"). F2: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share. F3: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and not designated as Rollover Shares was converted into the right to receive $10.50 per share in cash, without interest. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.94 · Expires 2030-03-02 | Direct | 0 |
Reported balance
After 2022-10-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-07 · Disposition to issuer · Disposed 525,434 · Balance 0 F4: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F5: The options, together representing a right to purchase 1,501,240 shares, consist of (i) 750,620 time-vesting options and (ii) 750,620 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2030-03-02 | Direct | 0 |
Reported balance
After 2022-10-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-07 · Disposition to issuer · Disposed 975,806 · Balance 0 F4: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F5: The options, together representing a right to purchase 1,501,240 shares, consist of (i) 750,620 time-vesting options and (ii) 750,620 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. F6: Exercise price reflects a reduction of $1.18 per award from original exercise price of $7.94 as part of a special dividend as previously disclosed in the Company's proxy statement for its 2022 annual meeting of stockholders. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-07 · Disposition to issuer · Disposed 355,561 · Balance 0 F7: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's outstanding Company restricted stock units ("RSUs") remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that each such RSU will settle in a number of Surviving Corporation Shares equal to the number of shares subject to the award immediately before the Effective Time multiplied by 0.01. F8: Represents 355,561 RSUs. RSUs are subject to a four year time-based vesting schedule with 25% vesting on March 28, 2023, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Farrell's continued service through the applicable vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares").
F2: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share.
F3: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and not designated as Rollover Shares was converted into the right to receive $10.50 per share in cash, without interest.
F4: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01.
F5: The options, together representing a right to purchase 1,501,240 shares, consist of (i) 750,620 time-vesting options and (ii) 750,620 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics.
F6: Exercise price reflects a reduction of $1.18 per award from original exercise price of $7.94 as part of a special dividend as previously disclosed in the Company's proxy statement for its 2022 annual meeting of stockholders.
F7: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's outstanding Company restricted stock units ("RSUs") remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that each such RSU will settle in a number of Surviving Corporation Shares equal to the number of shares subject to the award immediately before the Effective Time multiplied by 0.01.
F8: Represents 355,561 RSUs. RSUs are subject to a four year time-based vesting schedule with 25% vesting on March 28, 2023, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Farrell's continued service through the applicable vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2025 Filed Mar 6, 2025 22:47 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 10,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0000950170-25-034960 · ownership.xml · derivative · entry 4 FARRELL STEPHEN C · CIK 0001188757 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:47 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 10,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-25-034960 · ownership.xml · derivative · entry 3 FARRELL STEPHEN C · CIK 0001188757 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:47 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 10,000 | $8.35 | $83,500.00 |
DisclosureSEC source: 0000950170-25-034960 · ownership.xml · nonDerivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:47 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 10,000 | $5.54 | $55,400.00 |
DisclosureSEC source: 0000950170-25-034960 · ownership.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:05 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantRestricted Stock Units · Derivative | 200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029986 · ownership.xml · derivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs granted to the Reporting Person on February 26, 2025. RSUs will vest as to 1/3 of the shares subject to the award on Febraury 26, 2026, 2027 and 2028. F2 · derivative.expiration_date: Award of RSUs granted to the Reporting Person on February 26, 2025. RSUs will vest as to 1/3 of the shares subject to the award on Febraury 26, 2026, 2027 and 2028. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 4,010 | $0.00 Strike: $40.11 | $0.00 |
DisclosureSEC source: 0000950170-24-076869 · ownership.xml · derivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,010 Underlying: Common Stock · 4,010 shares Expires 2034-06-19 F1 · security: Reflects shares of restricted stock and options to purchase common stock granted on June 20, 2024, pursuant to the Corporation's annual non-employee director equity compensation program for the 2024-2025 term. These equity awards vest in full on the earlier of June 20, 2025, or the Corporation's 2025 Annual Meeting of Shareholders. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 2,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076869 · ownership.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,156 F1 · security: Reflects shares of restricted stock and options to purchase common stock granted on June 20, 2024, pursuant to the Corporation's annual non-employee director equity compensation program for the 2024-2025 term. These equity awards vest in full on the earlier of June 20, 2025, or the Corporation's 2025 Annual Meeting of Shareholders. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 23:03 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 921 | $31.21 | $28,744.41 |
DisclosureSEC source: 0001209191-24-000221 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,912 Read SEC document |
| November 06, 2023 Filed Nov 6, 2023 21:14 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 3,000 | $35.15 | $105,450.00 |
DisclosureSEC source: 0001209191-23-054514 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,991 Read SEC document |
| September 29, 2023 Filed Oct 4, 2023 00:07 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 715 | $40.18 | $28,728.70 |
DisclosureSEC source: 0001209191-23-051748 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,991 Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:41 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 3,127 | $0.00 Strike: $52.67 | $0.00 |
DisclosureSEC source: 0001209191-23-038172 · doc4.xml · derivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,127 Underlying: Common Stock · 3,127 shares Expires 2033-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest on the earlier of June 15, 2024 or the Corporation's 2024 Annual Shareholders Meeting, subject to his continued service through the vesting date. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:41 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 1,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038172 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restrictions on the 1709 restricted shares of common stock lapse on the earlier of June 15, 2024 or the Corporation's 2024 Annual Meeting, subject to Mr. Farrell's continued service through that date. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 19:26 UTC | Convey Health Solutions Holdings, Inc. CNVY · Entity 123140 | Disposition to issuerRestricted Stock Units · Derivative | 355,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-22-017700 · dp182275_4-farrell.xml · derivative · entry 4 FARRELL STEPHEN C · CIK 0001188757 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 355,561 shares Expires not disclosed F7 · security: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's outstanding Company restricted stock units ("RSUs") remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that each such RSU will settle in a number of Surviving Corporation Shares equal to the number of shares subject to the award immediately before the Effective Time multiplied by 0.01. F8 · derivative.exercise_price: Represents 355,561 RSUs. RSUs are subject to a four year time-based vesting schedule with 25% vesting on March 28, 2023, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Farrell's continued service through the applicable vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock. F7 · price: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's outstanding Company restricted stock units ("RSUs") remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that each such RSU will settle in a number of Surviving Corporation Shares equal to the number of shares subject to the award immediately before the Effective Time multiplied by 0.01. F8 · derivative.exercise_date: Represents 355,561 RSUs. RSUs are subject to a four year time-based vesting schedule with 25% vesting on March 28, 2023, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Farrell's continued service through the applicable vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock. F8 · derivative.expiration_date: Represents 355,561 RSUs. RSUs are subject to a four year time-based vesting schedule with 25% vesting on March 28, 2023, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Farrell's continued service through the applicable vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 19:26 UTC | Convey Health Solutions Holdings, Inc. CNVY · Entity 123140 | Disposition to issuerStock Option (right to buy) · Derivative | 975,806 | Not disclosed Strike: $6.76 | Not disclosed |
DisclosureSEC source: 0000950103-22-017700 · dp182275_4-farrell.xml · derivative · entry 3 FARRELL STEPHEN C · CIK 0001188757 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 975,806 shares Expires 2030-03-02 F4 · security: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F5 · security: The options, together representing a right to purchase 1,501,240 shares, consist of (i) 750,620 time-vesting options and (ii) 750,620 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. F6 · derivative.exercise_price: Exercise price reflects a reduction of $1.18 per award from original exercise price of $7.94 as part of a special dividend as previously disclosed in the Company's proxy statement for its 2022 annual meeting of stockholders. F4 · price: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F5 · derivative.exercise_date: The options, together representing a right to purchase 1,501,240 shares, consist of (i) 750,620 time-vesting options and (ii) 750,620 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 19:26 UTC | Convey Health Solutions Holdings, Inc. CNVY · Entity 123140 | Disposition to issuerStock Option (right to buy) · Derivative | 525,434 | Not disclosed Strike: $7.94 | Not disclosed |
DisclosureSEC source: 0000950103-22-017700 · dp182275_4-farrell.xml · derivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.01 per share · 525,434 shares Expires 2030-03-02 F4 · security: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F5 · security: The options, together representing a right to purchase 1,501,240 shares, consist of (i) 750,620 time-vesting options and (ii) 750,620 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. F4 · price: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01. F5 · derivative.exercise_date: The options, together representing a right to purchase 1,501,240 shares, consist of (i) 750,620 time-vesting options and (ii) 750,620 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 19:26 UTC | Convey Health Solutions Holdings, Inc. CNVY · Entity 123140 | Disposition to issuerCommon Stock, par value $0.01 per share | 163,373 | $10.50 | $1,715,416.50 |
DisclosureSEC source: 0000950103-22-017700 · dp182275_4-farrell.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,734 F1 · security: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"). F2 · security: In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share. F3 · security: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and not designated as Rollover Shares was converted into the right to receive $10.50 per share in cash, without interest. F3 · price: Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and not designated as Rollover Shares was converted into the right to receive $10.50 per share in cash, without interest. F1 · balance_after: On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares"). Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 22:32 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 5,765 | $0.00 Strike: $62.10 | $0.00 |
DisclosureSEC source: 0001209191-22-038092 · doc4.xml · derivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765 Underlying: Common Stock · 5,765 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest on the earlier of June 16, 2023 or the Corporation's 2023 Annual Shareholders Meeting, subject to his continued service through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 22:32 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 355 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038092 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 16, 2022, STAAR Surgical Company's shareholders approved an increase, effective as of June 2021, in the annual equity grants to non-employee directors, which resulted in the award of an additional 355 shares of restricted stock. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 16:41 UTC | Convey Health Solutions Holdings, Inc. CNVY · Entity 123140 | GrantRestricted Stock Units · Derivative | 355,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-040170 · tm2210674-5_4seq1.xml · derivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,561 Underlying: Common Stock, par value $0.01 per share · 355,561 shares Expires not disclosed F1 · derivative.exercise_price: Represents 355,561 restricted stock units. Restricted stock units are subject to a four year time-based vesting schedule with 25% vesting on March 28, 2023, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Farrell's continued service with Convey Health Solutions Holdings, Inc. (the "Issuer") through the applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units will be settled in common stock. F1 · derivative.exercise_date: Represents 355,561 restricted stock units. Restricted stock units are subject to a four year time-based vesting schedule with 25% vesting on March 28, 2023, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Farrell's continued service with Convey Health Solutions Holdings, Inc. (the "Issuer") through the applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units will be settled in common stock. F1 · derivative.expiration_date: Represents 355,561 restricted stock units. Restricted stock units are subject to a four year time-based vesting schedule with 25% vesting on March 28, 2023, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Farrell's continued service with Convey Health Solutions Holdings, Inc. (the "Issuer") through the applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units will be settled in common stock. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 21:54 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 850 | $0.00 Strike: $154.96 | $0.00 |
DisclosureSEC source: 0001209191-21-043359 · doc4.xml · derivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850 Underlying: Common Stock · 850 shares Expires 2031-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest on the earlier of June 24, 2022 or the Corporation's 2022 Annual Shareholders Meeting. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 21:54 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 404 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043359 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The restrictions on the 404 restricted shares of common stock lapse on the earlier of June 24, 2022 or the Corporation's 2022 Annual Meeting, subject to Mr. Farrell's continued service through that date. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 06:09 UTC | Convey Health Solutions Holdings, Inc. CNVY · Entity 123140 | PurchaseCommon Stock, par value $0.01 per share | 45,000 | $13.00 | $585,000.00 |
DisclosureSEC source: 0001104659-21-082935 · tm2120200-1_4seq1.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,862 F1 · price: The reported price is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $12.82 to $13.10 per share. The reporting person hereby undertakes to provide to Convey Holding Parent, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2021 Filed May 28, 2021 20:31 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 5,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0001209191-21-036545 · doc4.xml · derivative · entry 6 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2026-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed May 28, 2021 20:31 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Disposition to issuerCommon Stock | 5,000 | $150.00 | $750,000.00 |
DisclosureSEC source: 0001209191-21-036545 · doc4.xml · nonDerivative · entry 4 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,808 Read SEC document |
| May 28, 2021 Filed May 28, 2021 20:31 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 5,000 | $5.54 | $27,700.00 |
DisclosureSEC source: 0001209191-21-036545 · doc4.xml · nonDerivative · entry 3 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:31 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 5,000 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001209191-21-036545 · doc4.xml · derivative · entry 5 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:31 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Disposition to issuerCommon Stock | 5,000 | $135.00 | $675,000.00 |
DisclosureSEC source: 0001209191-21-036545 · doc4.xml · nonDerivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,808 Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:31 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 5,000 | $7.14 | $35,700.00 |
DisclosureSEC source: 0001209191-21-036545 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 5,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0001209191-21-034878 · doc4.xml · derivative · entry 3 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2026-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Disposition to issuerCommon Stock | 5,000 | $120.00 | $600,000.00 |
DisclosureSEC source: 0001209191-21-034878 · doc4.xml · nonDerivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,808 Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 5,000 | $5.54 | $27,700.00 |
DisclosureSEC source: 0001209191-21-034878 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2021 Filed May 18, 2021 20:47 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock Options · Derivative | 5,328 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001209191-21-033541 · doc4.xml · derivative · entry 3 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,328 shares Expires 2025-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2021 Filed May 18, 2021 20:47 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Disposition to issuerCommon Stock | 5,328 | $113.87 | $606,699.36 |
DisclosureSEC source: 0001209191-21-033541 · doc4.xml · nonDerivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,808 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.86 to $117.81, inclusive. Read SEC document |
| May 17, 2021 Filed May 18, 2021 20:47 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 5,328 | $7.14 | $38,041.92 |
DisclosureSEC source: 0001209191-21-033541 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2020 Filed Aug 4, 2020 21:21 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 2,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-044762 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,808 F1 · shares: The restrictions on the 2117 restricted shares of common stock awarded on his election to the Board of Directors lapse on the earlier of July 30, 2021 or the Corporation's 2021 Annual Meeting, subject to his continued service through that date. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 21:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001493152-20-012541 · ownership.xml · derivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: Will become exercisable on July 1, 2021, based upon continued service on the board of directors. Read SEC document |
| July 01, 2019 Filed Jul 4, 2019 01:18 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001209191-19-041310 · doc4.xml · derivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2029-06-30 F1 · derivative.exercise_date: Will become exercisable on June 30, 2020, based upon continued service on the board of directors. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 21:24 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 8,536 | $0.00 Strike: $29.39 | $0.00 |
DisclosureSEC source: 0001209191-19-038819 · doc4.xml · derivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,536 Underlying: Common Stock · 8,536 shares Expires 2029-06-19 F1 · derivative.exercise_date: These stock options vest in full on the earlier of June 20, 2020 or the Corporation's 2020 Annual Meeting, subject to Mr. Farrell's continued service through the vesting date. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 22:16 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 40,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001209191-18-041298 · doc4.xml · derivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2023-06-30 F1 · derivative.exercise_date: Will become exercisable on June 30, 2019, based upon continued service on the board of directors. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:45 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 3,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038346 · doc4.xml · nonDerivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,691 F1 · shares: The restrictions on the 3,691 restricted shares of common stock lapse on the earlier of June 14, 2019 or the Corporation's 2019 Annual Meeting, subject to Mr. Farrell's continued service through that date. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 21:12 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 1,206 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001209191-18-020641 · doc4.xml · derivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,206 Underlying: Common Stock · 1,206 shares Expires 2028-03-14 F1 · security: These stock options vest in full on the earlier of June 14, 2018 or the Corporation's 2018 Annual Meeting, subject to Mr. Farrell's continued service through the vesting date. F1 · derivative.exercise_date: These stock options vest in full on the earlier of June 14, 2018 or the Corporation's 2018 Annual Meeting, subject to Mr. Farrell's continued service through the vesting date. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 23:41 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 20,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-17-043772 · doc4.xml · derivative · entry 2 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2022-06-30 F1 · derivative.exercise_date: Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:11 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 19,841 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0001209191-17-040109 · doc4.xml · derivative · entry 1 FARRELL STEPHEN C · CIK 0001188757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,841 Underlying: Common Stock · 19,841 shares Expires 2027-06-12 F1 · derivative.exercise_date: These 19,841 stock options vest in full on the earlier of June 13, 2017 or the Corporation's 2018 Annual Meeting, subject to Mr. Farrell's continued service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.